- Home
- OPTT vs CANF Comparison
OPTT vs CANF Comparison
Compare OPTT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTT | CANF |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 4.9M |
| IPO Year | 2006 | 2011 |
Fundamental Metrics
Financial Performance| Metric | OPTT | CANF |
|---|---|---|
| Price | $0.43 | $1.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $45.00 | $7.50 |
| AVG Volume (30 Days) | ★ 606.2K | 27.5K |
| Earning Date | 12-14-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,737,000.00 | N/A |
| Revenue This Year | $286.98 | N/A |
| Revenue Next Year | $131.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.17 |
| 52 Week High | $3.23 | $10.40 |
Technical Indicators
Market Signals| Indicator | OPTT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 31.61 |
| Support Level | $0.40 | N/A |
| Resistance Level | $0.52 | $2.27 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 20.65 | 33.00 |
Price Performance
Historical ComparisonAbout OPTT Ocean Power Technologies Inc.
Ocean Power Technologies Inc is specializing in intelligent maritime solutions. These solutions include a variety of as a service systems, including Data as a Service (DaaS), Robotics as a Service (RaaS), and Power as a Service (PaaS). It design, manufacture, deploy, and operate these systems for defense, security, subsea infrastructure, offshore oil and gas, offshore energy, marine research, and communication markets. The company operates as one operating segment. Majority of revenue comes from Europe followed by North & South America; and followed by Asia and Australia.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.